Medicine and Dentistry
Breast Cancer
100%
Metastatic Breast Cancer
39%
Neoplasm
30%
BRCA1
16%
Estrogen Receptor
14%
Metastatic Carcinoma
14%
Trastuzumab
13%
Cohort Analysis
13%
Overall Survival
12%
Maturity Onset Diabetes of the Young
12%
Circulating Tumor DNA
11%
Cancer Risk
11%
Germ Cell
10%
Systemic Therapy
10%
Hormone Therapy
10%
Epidermal Growth Factor Receptor 2
9%
Gamma Urogastrone
9%
COVID-19
9%
Ex Vivo
9%
Diseases
9%
Neoadjuvant Chemotherapy
8%
Paclitaxel
8%
Diabetes
8%
Microalbuminuria
7%
Malignant Neoplasm
7%
Hazard Ratio
7%
Polyethylene Terephthalate
7%
Contralateral
7%
Tamoxifen
7%
Systematic Review
7%
Aneuploidy
7%
Quality of Life
6%
BRCA2
6%
Albumin
6%
Homologous Recombination
6%
Biopsy Technique
6%
Breast Tumor
6%
Odds Ratio
6%
Hormone Receptor
5%
Treatment Response
5%
Ovarian Cancer
5%
Positron Emission Tomography-Computed Tomography
5%
Diethylstilbestrol
5%
Impaired Glucose Tolerance
5%
Allele
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
83%
Tamoxifen
37%
Metastatic Breast Cancer
27%
Chemotherapy
24%
Neoplasm
22%
Endoxifen
22%
Paclitaxel
21%
Trastuzumab
20%
Overall Survival
14%
Cohort Study
13%
Pharmacokinetics
12%
Circulating Tumor DNA
12%
Diabetes Mellitus
10%
Malignant Neoplasm
10%
Cyclin Dependent Kinase 4
9%
Subcutaneous Injection
9%
Endocrine Therapy
8%
Carboplatin
8%
CYP2D6
8%
Olaparib
7%
Estrogen Receptor
7%
Diseases
6%
Von Willebrand Factor
6%
Non Insulin Dependent Diabetes Mellitus
6%
C Reactive Protein
6%
Microalbuminuria
6%
Palbociclib
5%
Cardiovascular Mortality
5%
Progression Free Survival
5%
Solid Malignant Neoplasm
5%
Abemaciclib
5%
Receptor
5%
Taxane
5%
Therapeutic Drug Monitoring
5%
Clinical Study
5%
Pertuzumab
5%
Biochemistry, Genetics and Molecular Biology
BRCA1
19%
BRCA2
14%
Circulating Tumor DNA
14%
Germ Cell
11%
Germline
11%
Homologous Recombination
9%
Estrogen Receptor
9%
C-Reactive Protein
8%
Genomics
7%
Quality Adjusted Life Year
7%
Allele
7%
Aneuploidy
7%
Cardiovascular Mortality
6%
VCAM-1
6%
Overall Survival
6%
Blood Plasma
6%
Von Willebrand Factor
6%
DNA Analysis
5%
Cohort Study
5%
Prospective Study
5%